The shared mechanism: ghrelin receptor activation

All three GHRPs act as agonists at the growth hormone secretagogue receptor 1a (GHS-R1a) — also known as the ghrelin receptor. This receptor is expressed on pituitary somatotrophs, where its activation triggers calcium mobilisation and growth hormone exocytosis. Crucially, GHS-R1a activation also suppresses somatostatin release from the hypothalamus — removing the primary brake on pituitary GH secretion at the same time the accelerator is applied. This dual effect is why GHRPs combine synergistically with GHRH analogues like CJC-1295 or Tesamorelin: the GHRH amplifies the stimulatory signal while the GHRP removes the inhibitory counter-signal, producing GH release substantially greater than either compound alone.

The ghrelin receptor was identified by Kojima et al. in 1999 (Nature, PMID 10604470) when the endogenous ligand ghrelin was isolated from stomach tissue. All three GHRPs under discussion are synthetic peptides developed before ghrelin's discovery, originally characterised empirically by their GH-releasing effects before the receptor was formally identified. Understanding the shared receptor basis explains both why all three compounds produce qualitatively similar GH stimulation and why their differences are driven by binding affinity variations, receptor subtype selectivity, and downstream signalling divergence rather than fundamentally different mechanisms.

GHRP-2: maximum pulse amplitude with moderate cortisol co-stimulation

GHRP-2 (also called KP-102) is a hexapeptide that produces the highest GH pulse amplitude of the three compounds at equivalent doses. This potency advantage comes with a trade-off: GHRP-2 also stimulates a moderate increase in cortisol (via ACTH) and prolactin, particularly at higher doses. The magnitude of cortisol elevation is generally less than physiologically significant thresholds at research doses — a 2003 study by Ghigo et al. in J Clin Endocrinol Metab documented a dose-dependent cortisol response to GHRP-2 administration in healthy adults, with peak cortisol remaining within the normal physiological range at standard research doses.

GHRP-2 is the preferred compound for research protocols where maximum GH pulse amplitude is the primary variable — body composition studies, muscle hypertrophy research, and protocols where the strength of the GH secretory response itself is the outcome of interest. The moderate cortisol co-stimulation is generally acceptable in short-term protocols and becomes more relevant in longer duration studies where cumulative cortisol effects may influence outcomes. See the dosing guide for GHRP-2 dose calculator and reconstitution specifications.

GHRP-6: strong appetite co-stimulation as a research variable

GHRP-6 is the oldest of the three compounds — a hexapeptide that was among the first GHRPs characterised in the early 1980s by Bowers et al. It produces robust GH stimulation alongside significant appetite stimulation through its strong ghrelin receptor activation. Ghrelin is an orexigenic (appetite-stimulating) hormone, and GHRP-6's strong ghrelin receptor agonism produces hunger that is noticeably more pronounced than either GHRP-2 or Ipamorelin at equivalent GH-releasing doses. This is not a side effect to be managed — it is a research variable in its own right.

GHRP-6 is specifically useful in research protocols where appetite stimulation or orexigenic effects are themselves the study outcome. In animal models of cachexia, chronic illness, and appetite disorders, GHRP-6 has been studied as a GH-independent appetite stimulant. It also stimulates cortisol and prolactin moderately, at levels comparable to GHRP-2. For protocols where appetite effects are unwanted, GHRP-6 is typically not the compound of choice. The GHRP-6 entry in the Peptide Hub dosing guide includes the full dose calculator.

Ipamorelin: selectivity as the defining feature

Ipamorelin is a pentapeptide — one amino acid shorter than the hexapeptide GHRPs above — and its defining characteristic is selectivity. At research doses, Ipamorelin produces GH release without significant elevation of cortisol, prolactin, ACTH, or LH. It also produces minimal appetite stimulation compared to GHRP-6, and less cortisol co-stimulation than GHRP-2. This selectivity profile makes Ipamorelin the preferred GHRP for combination protocols where clean GH stimulation is the research objective and avoiding co-stimulation of stress hormones or appetite-regulating pathways is a priority.

The trade-off is pulse amplitude: Ipamorelin's GH peak is somewhat lower than GHRP-2 at equivalent doses. In practice for most research applications, this difference is outweighed by the cleaner hormonal profile — particularly in longer-duration protocols where repeated cortisol or prolactin elevation could confound results or be poorly tolerated. For the CJC-1295/Ipamorelin combination stack specifically, Ipamorelin is chosen over GHRP-2 or GHRP-6 because the GHRH-mediated amplitude amplification compensates for the lower baseline GHRP amplitude, producing robust combined GH release with the selectivity advantage intact. See our CJC-1295 and Ipamorelin stack guide for the full protocol.

GHRP dosage comparison chart

Combining GHRPs with GHRH analogues

All three GHRPs produce significantly greater GH release when combined with a GHRH analogue than when used alone. The synergistic effect is mechanistically predictable: the GHRH component (CJC-1295, Tesamorelin, Sermorelin) activates the GHRH receptor to stimulate GH synthesis and amplify pulse amplitude, while the GHRP simultaneously activates the GHS-R1a receptor and suppresses somatostatin, removing the inhibitory counter-signal. The combined effect is greater than the sum of the individual components — a pharmacological principle confirmed in multiple human studies beginning with the foundational work of Alba et al. in 1994.

For most combination protocols, the GHRP is administered in the same injection as the GHRH analogue at the same time point. GHRP-2 in the 4X Blend is combined with Tesamorelin, Ipamorelin, and MGF for a comprehensive body composition protocol. Ipamorelin in the 2X and 3X Blends is paired with Tesamorelin for a cleaner GH stimulation approach. The choice of GHRP for combination protocols should be guided by the same selectivity considerations that apply to GHRP monotherapy. Full calculator references for each combination are in the dosing guide, and individual compound profiles are in the Ipamorelin and GHRP-2 database entries.

Timing and fasting requirements

Fasted administration is essential for all three GHRPs. Elevated insulin — driven by carbohydrate or fat intake — directly suppresses GH release at the pituitary level and counteracts the GH-stimulating effect of the GHRP. Protocols typically specify morning administration at least 30–45 minutes before any food, or pre-sleep administration at least 2–3 hours after the last meal. The pre-sleep timing has an additional rationale: it amplifies the body's largest endogenous GH pulse, which occurs within the first 90 minutes of slow-wave sleep, rather than replacing it. The 5 days on / 2 days off schedule prevents receptor desensitisation that occurs with continuous daily stimulation in animal models of GHS-R1a downregulation.

---

Editorial Note: This article is published for research and educational purposes only. Peptide Hub does not sell peptides, receive commissions from peptide vendors, or endorse any specific supplier. All compounds discussed are research peptides not approved for human therapeutic use except where specifically noted. This is not medical advice.

Sources

1. Kojima M, et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. PubMed
2. Bowers CY, et al. (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. PubMed
3. Ghigo E, et al. (2003). GHRP-2 and the ghrelin system — clinical implications. J Clin Endocrinol Metab. PubMed
4. Alba M, et al. (1994). Both growth hormone-releasing peptide-2 and GH-releasing hormone amplify pulsatile GH secretion in healthy individuals. J Clin Endocrinol Metab. PubMed
5. Arvat E, et al. (2001). Preliminary evidence that ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest. PubMed